SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-050081
Filing Date
2023-06-20
Accepted
2023-06-20 16:30:21
Documents
14
Period of Report
2023-06-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea180601-8k_allarity.htm   iXBRL 8-K 30775
2 PRESS RELEASE ea180601ex99-1_allarity.htm EX-99.1 16869
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3896
  Complete submission text file 0001213900-23-050081.txt   234945

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE allr-20230620.xsd EX-101.SCH 2959
5 XBRL LABEL FILE allr-20230620_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE allr-20230620_pre.xml EX-101.PRE 22359
8 EXTRACTED XBRL INSTANCE DOCUMENT ea180601-8k_allarity_htm.xml XML 3714
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 231025576
SIC: 2834 Pharmaceutical Preparations